Clinical trial
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic…
NCT00414765 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00414765 |
|---|---|
| Title | Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma |
| Official title | Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma or Metastatic Melanoma With Immunologic Correlative Studies |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Metastatic Renal Cell Carcinoma, Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | Aldesleukin |
| Enrollment | 26 |
| Start date | Sep 3, 2008 |
| Primary completion | Mar 28, 2010 |
| Completion | Mar 28, 2010 |
| First posted | Dec 22, 2006 |
| Last update posted | Jun 8, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: